Background: People who inject drugs (PWID) account for roughly 13% of the prevalent HIV/AIDS population outside of sub-Saharan Africa, and access to opioid substitution treatment (OST) is limited in many settings globally. OST likely facilitates access to HAART, yet sparse evidence is available to support this hypothesis. Our objective was to determine the causal impact of OST exposure on HAART adherence among HIV-positive PWID in a Canadian setting.
Introduction
Globally, it is estimated that there may be as many as 15.9 million (range 11.0-21.2 million) people who inject drugs (PWID), with as many as 3 million (range 0.8-6.6) being HIV-positive [1] ; this accounts for roughly 13% of all people with HIV/AIDS outside of sub-Saharan Africa [2, 3] . The largest numbers of injectors were found in China, the USA and Russia, where estimates of HIV-prevalence among PWID were 12, 16 and 37%, respectively [3] . Past studies have shown that HAART can reduce plasma HIV RNA thereby reducing morbidity and mortality and reducing HIV transmission [4] [5] [6] , with a specific demonstration of the effect of diminishing plasma viral load on HIV incidence within a community of urban PWID in a Canadian setting [7] . Unfortunately, PWID are known to have poor access and adherence to HAART. A recently published global survey suggests that only four out of every 100 HIV-positive PWID (range: [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] are accessing HAART, with many of those concentrated in Europe, and sparse reporting in many regions [3] .
Opioid substitution treatment (OST) with methadone or buprenorphine is currently indicated for the treatment of opioid dependence in most developed-world countries [3] . In British Columbia (BC) Canada, methadone is covered for reimbursement under standard provincial drug benefit formularies, although buprenorphine is available as a second-line option at the physician's discretion. There is clearly a potential for positive synergies between OST and HAART for HIV-positive, opioid-dependent individuals, yet OST remains highly restricted in many settings [3] . Several studies have reported that methadone treatment was independently associated with decreased time to HAART initiation [8, 9] . Engagement in OST has also been associated with decreases in HIV risk behaviour and adherence to HAART and resulting health gains [10] [11] [12] [13] [14] . Once HAART adherent, PWID have been noted to have a similar risk of mortality to noninjectors [15] . Although OST has no direct effect on HIV disease progression or HIV-related mortality, it has the potential to improve HAARTuptake and adherence, which impact these more distal outcomes.
Measuring the causal impact, or the true extent to which OST may influence HAART adherence is, however, complicated by competing hypotheses on the effect of OST on HAART, and HAART on OST. Specifically, OST is hypothesized to influence HAART adherence via the stability provided to its clients through reduced need to constantly address opioid withdrawal and craving [16] . Linkage to the healthcare system afforded by stable access to OST may further influence HAART adherence; however, the same hypothesis can be made for the effect of HAART on OST [17] . Marginal structural models are designed specifically to handle time-varying confounding effects such as that of HAART on OST in our context, allowing for causal interpretations of results.
Thus, our objective is to determine the causal effect of OSTexposure, as well as a range of other individual-level factors, on HAART medication refill adherence among HIV-positive PWID using data from a linked populationlevel database with comprehensive OST and HAART dispensation records.
Materials and methods

Patient population
This study was based on a provincial-level linkage of seven health administrative databases and disease registries, including the province-wide antiretroviral dispensation, virology and HIV-testing registries [antiretroviral dispensations, plasma viral load (pVL), CD4 þ cell count tests, nominal HIV diagnoses], the Medical Services Plan database (physician billing records), the discharge abstract database (hospitalizations), the BC PharmaNet database (nonantiretroviral drug dispensations) and the BC Vital statistics database (deaths). Further details regarding the construction of the HIV-positive cohort and available databases were described elsewhere [18] .
We selected all individuals identified as HIV-positive and either identified as having a history of injection drug use at diagnosis or having accessed OST before HAART eligibility, as indicated by methadone or buprenorphine dispensation records in the BC PharmaNet database, from 1 April 1996 to 31 March 2010. OST dispensations were identified by unique drug identification numbers (DINs). These codes encompass current and past DINs used for the medications in question and are specific to indications for opioid dependence (as opposed to pain). Previous studies have defined methods to clean and process PharmaNet data for accurate estimation of OST episodes [19] . OST dispensation record capture was complete for the province of BC.
For each individual, we consider follow-up data from the point of initial HAART eligibility, as determined by IAS-USA criteria from 1996 to 2010, based on CD4 þ cell count and pVL tests and AIDS-defining illness after the HIV diagnosis date, or by HAART initiation. Individuals were followed up until death, administrative loss to follow-up or censorship (ongoing care as of 30 March 2010). Administrative loss was defined as no records in any of the linked databases for a period of at least 18 months. The database is thus arranged longitudinally, with one row per month of observation following the date of HAARTeligibility, until the last observed contact date within the database or the end of the study followup period.
The study cohort was followed in a unique environment wherein medical care (HIV and non-HIV related), antiretroviral treatment and laboratory monitoring is fully subsidized by the BC provincial government for people with HIV/AIDS. Antiretroviral drugs are centrally distributed according to provincial treatment guidelines that have remained consistent with those put forward by the International AIDS Society-USA ('IAS-USA') since the summer of 1996 [20] and until the most recent guidelines released in 2012 [21] . Antiretroviral medication and viral load data capture in the BC-CfE registries are complete for the population of individuals with HIV/AIDS in the province, and CD4 þ cell count data capture have previously been estimated at 80% [22] . This study received approval from the University of British Columbia/Providence Healthcare Research Ethics Board.
Measures
The dependent variable in the study was HAART adherence, defined as at least 95% pharmacy refill adherence in a given calendar month. Exposure to OST, defined by at least 95% days of OST dispensed in a calendar month, was the key independent variable considered. We considered HAART medication refill adherence as our primary outcome as opposed to more distal outcomes such as viral suppression or HIV-related mortality because it is the most proximal outcome in the causal pathway between OST and HIV-related outcomes, and because OST is not known to have a direct effect on HIV disease progression or HIV-related mortality.
We also considered a selection of other baseline and timevarying covariates hypothesized to be associated with the dependent and primary independent variable. Baseline covariates included age (30-39, 40-49, 50þ) , sex, aboriginal ethnicity, BC health authority of residence, CD4 þ cell count (<200, 200-499, 500 cells/ml), calendar year (1996-1999, 2000-2003, 2004-2010) and AIDS status, all made available through the BC-CfE HIV registry. The Charlson comorbidity index (CCI) score [23] (1 vs. 0) and OST history (number of prior OST episodes) at the time of HAART eligibility were also incorporated, as well as time-varying measures of CD4 þ cell count, health authority of residence, time since HAART eligibility, AIDS status and CCI.
Statistical analysis
Marginal structural models are designed to handle cases in which time-dependent variables are simultaneously confounders of the effect of interest and are predicted by previous treatment. Past HAART medication refill adherence can be considered a time-dependent confounder for the effect of OST on future HAART adherence, as it may be hypothesized to not only predict future HAART adherence but also subsequent initiation of OST, and as past OST history is an independent predictor of subsequent HAART adherence. The hypothesized relationship is characterized in the directed acyclic graph illustrated in Fig. 1 . We hypothesized that exposure to OST at time t affects HAART medication refill adherence at time t þ 1, which in turn influences OST exposure at time t þ 2. Time-invariant and timevarying confounding at time t affects OST exposure, HAART medication refill adherence and confounders at time t þ 1, and those confounders at t þ 1 are also predicted by OST exposure at t. This relationship is analogous to the longitudinal relationship between zidovudine therapy and CD4 þ cell count, which has served as an example of a repeated-measures application of marginal structural modelling [24] .
To control for time-varying confounding in the exposure-outcome relationship, inverse probability of treatment weights (IPTWs) were estimated for each time point of the study. Under the four assumptions of consistency, exchangeability, positivity and no misspecification of the model used to estimate the weights, weighting intuitively creates a pseudo-population in which the exposure is independent of the measured confounders [25] . The pseudo-population is the result of assigning each participant a weight that is inversely proportional to the participant's probability of receiving her own exposure history. In such a pseudo-population, one can regress the outcome on the exposure using a conventional regression model that does not include the measured confounders as covariates. Fitting a model in the pseudo-population is equivalent to fitting a weighted model in the study population. The parameters of such weighted regression models, which equal the parameters of marginal structural models [26] , can be used to estimate the average causal effect of exposure in the original study population.
Weighted estimation of the parameters of marginal structural models requires fitting several models: the structural (i.e. weighted) model; the exposure model; and the censoring model. The exposure and censoring models were used to estimate the IPTW by a pooled logistic regression. The IPTWs were constructed according to their standard formulation [25] , and the model specification was presented in a supplementary appendix, http://links.lww.com/QAD/A670. The final structural model was performed using PROC GEN-MOD [generalized estimating equation (GEE) regression model using independent working covariate matrix] for Effect of opioid substitution treatment on HAART Nosyk et al. 967 HAART medication refill adherence (95%), with independent variables of OST (95%), and baseline covariates included [27] . All analyses were executed using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Sensitivity analysis
We considered a range of sensitivity analyses to protect against model misspecification. Correct model specification applies to exposure, censoring and structural (weighted) models. In the context of the structural model, we considered subgroup analyses on those having no OSTexperience prior to HAARTeligibility and those having OST experience. We also considered beginning follow-up at HAART initiation, as well as alternate definitions of OST receipt, including OST adherence at the minimum effect dose (60 mg/day) [28, 29] , OST adherence during periods of maintenance treatment (excluding periods of dose titration and tapering) [30] and alternate adherence thresholds for both HAART and OST adherence.
In the context of the exposure/censoring models used to construct the IPTW, first, we compared stabilized and unstabilized IPTW. We also considered truncated (stabilized) weights, assessing the stability of the IPTW (i.e. evaluating mean, standard deviation of IPTW) for appropriateness. We included variables statistically associated with HAART medication refill adherence for exposure/censoring models. For the assumption of positivity or correct model specification to hold, the mean of IPTWs should be approximately equal to one.
Results
Characteristics of study cohort
Study sample selection is outlined in Fig. 2 . Among 12 349 HIV-positive individuals in the STOP HIV/AIDS cohort, a total of 2928 (23.7%) HIV-positive individuals were identified as ever having received OST or having a history of injection drug use at HIV diagnosis. After excluding 584 individuals whose HAART eligibility status could not be verified and another 492 due to insufficient follow-up and unknown injection drug use status at HAART eligibility (i.e. identified as PWID through OST receipt after HAART eligibility only), the selected study cohort consisted of 1852 HIV-positive PWID.
The study sample was 34% female, median-aged 35 years and 27% of known Aboriginal ethnicity (Table 1) . At the time of HAART eligibility or HAART initiation, 20% were on OST, and 39% had ever accessed OST in the past; individuals had a median of 0 (interquartile range: 0-1) prior OST episodes. The majority (46%) of the cohort became HAARTeligible pre-2000. By the end of followup, 50% of the cohort accessed OST.
Longitudinal exposure to opioid substitution treatment and HAART The cohort was followed up for a median duration of 5.5 years (2.2-10.1), and 25% of the cohort died during follow-up (Table 2) . Individuals spent a median 44% of follow-up on HAART, 0% of follow-up on OST and 0% on both forms of treatment, jointly. Most importantly, individuals spent a median of 56% of the time they were in OSTreceiving HAART; when out of OST, individuals were receiving HAART only 38% of the time.
Inverse probability of treatment weight estimation
Variables that were associated with the outcome were selected for models for weight estimation. stable, with means at 1.00 and smaller standard deviations (IPTW model results and weights are presented in a supplementary appendix, http://links.lww.com/QAD/ A670). Truncating weights at the first and 99th or fifth and 95th percentile resulted in smaller standard deviations with means close to 1. Stabilized, truncated weights (at the first and 99th percentiles) were thus used in baseline models.
Causal effect of opioid substitution treatment on HAART
Results of the structural model are presented in 
Sensitivity analysis on the effect of opioid substitution treatment on HAART
Baseline results indicating a positive and statistically significant effect of OST on HAART were supported by the results of our sensitivity analyses. We considered two changes in the classification of OST exposure: requiring treatment at the minimum effective dose, and requiring that individuals be at a stable maintenance dose to be classified as exposed. In each case, AORs in the structural model decreased compared with the baseline model formulation with truncated IPTW, but remained statistically significantly positive. Further, models with alternate adherence thresholds for both HAART and OST adherence had similar results compared with the baseline model. We also considered subgroups of individuals beginning follow-up at HAART initiation, and individuals with and without prior OST exposure at HAART eligibility. Odds ratios were higher than in the baseline model formulation for those with no prior exposure to OST.
Discussion
Using a linked population-level database capturing HIVpositive PWID in a Canadian province, this study has demonstrated a 68% increase in the odds of HAART medication refill adherence due to OST exposure. The results were robust to a number of sensitivity analyses focusing on the assumptions of correct model specification inherent in the selected modelling approach.
These results largely confirm prior studies showing a positive association between OST and HAART adherence (measured within the same time period) in settings in which office-based OST is available; however the role of continuing injection drug use (in particular heroin use) was unclear [10, 11, 13] . Specifically, Palepu et al. [11] controlled for time-varying heroin use and found that OST was independently positively associated with adherence, with an AOR of 1.52 (95% CI 1.16-2.00). In contrast, Roux et al. [13] found that the odds of nonadherence for those engaged in OST and not injecting were no different from those currently opioid-abstinent, but patients reporting drug injection during OST had a two-fold risk of nonadherence compared with those currently abstinent.
These analyses were executed through prospective cohort studies that were able to ascertain self-reported drug use alongside time-varying measures of OST exposure and HAART medication refill adherence. However, in both studies, their measurement of OST exposure was coarse, capturing 'ever accessing OST in the past 6 months'.
Although we did not observe time-varying measures of the use of opioids, given the specificity with which we measured OST exposure, the high threshold for OST adherence and the blockade effect of methadone and buprenorphine against illicit opioid use, periods of OST exposure likely featured limited, to no illicit opioid use. Inclusion of this covariate would therefore constitute a violation of the assumption of positivity in this context [25] .
Adjusting for the effect of prior HAARTon OST resulted in a difference of 0.23 in the magnitude of the odds ratio, or 14% compared with unweighted (GEE) models. We believe this approximates the effect of healthcare system linkage through HAART on OST receipt. Although the remaining positive effect of OST on HAART cannot be separated into its hypothesized explanations ('stabilized lifestyle' and 'linkage to the healthcare system'), we expect that healthcare system linkage through OST had a larger effect than the contrary. As opposed to antiretrovirals, certification is required to prescribe methadone or buprenorphine, making linkage to HIV care through OST prescribers perhaps more plausible than the contrary, as HAART prescribers with no OSTexemption would have to refer clients elsewhere. The complex casemix of this patient population, featuring a high prevalence of comorbid HIV, hepatitis C virus (HCV), mental health conditions and pain [31, 32] , is just one of the factors that challenge access and physician participation in the treatment of this patient population [33] . Comprehensive and integrated healthcare, incorporating addiction treatment in primary care [34] , is clearly critical for the successful treatment of HIV-positive individuals with opioid dependence. In this regard, integrated 'directly observed therapy' programmes, combining OST and HAART medication pickups, have shown mixed results, but continue to be assessed [35, 36] . Our findings also have important implications for healthcare resource allocation decisions. The benefits in HAART medication refill adherence caused by exposure to OST lead directly to improved disease progression profiles [37] , as well as reductions in infectivity through viral suppression [4] [5] [6] [7] ; these secondary benefits of OST should be incorporated directly into simulation models developed to determine the long-term cost-effectiveness of competing OST modalities [38] and population-level OSTuptake [39, 40] .
We note that although maintenance-oriented treatment is recommended both federally and provincially in British Columbia, Canada, in some cases, patterns of medication dispensation resembling detoxification treatment have been observed [30] . In the baseline model, we did not distinguish between these two modalities because there is no explicit indication within our health administrative databases to differentiate them. Nonetheless, we considered an alternate definition of reaching a minimum effective dose of 60 mg/day as an indirect measure of maintenance treatment receipt in sensitivity analysis. Furthermore, buprenorphine is not commonly used in BC, with the medication only gaining approval as a second-line treatment in 2010, initially only under special authority [33] . As such, buprenorphine was only observed in only one patient month of follow-up within the study sample.
Our study offers the advantages of a complete population of HIV-positive PWID accessing OST and specific measurement of exposure and outcome, allowing for narrow repeated observation periods and a clear temporal ordering in cause and effect. Nonetheless, several limitations require careful consideration. First, although the study was population-based and featured complete follow-up data with precise measurement of exposure and outcome, the underlying policies and clinical practice in BC -specifically, maintenance-oriented OST with available office-based prescription and community pharmacy-based dispensation, and universal and comprehensive coverage for HIV medications and care -may differ substantially from other settings. Second, those identified as PWID at HIV diagnosis may have injected substances other than opioids exclusively, thus precluding indication for OST. Although we suspect the proportion of such individuals to be small, their inclusion may have attenuated the estimated effect of OST on HAART. Otherwise, although we judge the measurement of exposure and outcome to be at a high level, HAART adherence was measured according to pharmacy refill compliance records, which may overestimate true adherence, albeit equally during periods of OSTexposure and nonexposure (nondifferential outcome misclassification), thus resulting in perhaps attenuated odds ratios.
Finally, although we have tested the potential effects of model misspecification extensively, there remains potential unmeasured confounding due to depressive symptoms, alcohol use and potentially other drug use, previously identified as factors independently negatively associated with HAART adherence [13] . The population under study likely included individuals with these behaviours; therefore, our results can be interpreted as a weighted average effect; samples with high levels of mental health comorbidity and/or polydrug use may have an attenuated effect, whereas nonexposed samples may have a larger effect. Otherwise, the causal interpretation of the results of marginal structural model relate to the affirmation of temporal ordering and control for key time-varying confounders; other interpretations of causal inferences consider a number of additional criteria, including repeated observation of the effect in different populations and study settings [41, 42] . Cautious interpretations of the results are therefore recommended.
This study demonstrates the substantial benefits of OST in linking HIV-positive opioid-dependent individuals into HAART in a universal healthcare setting with freely available HAART. There is a priority to expand access to OST particularly within HIV-positive populations, to optimize HIV treatment uptake and adherence and its subsequent individual and population health and economic benefits. 
